Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 164


Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure.

Elkayam U, Tasissa G, Binanay C, Stevenson LW, Gheorghiade M, Warnica JW, Young JB, Rayburn BK, Rogers JG, DeMarco T, Leier CV.

Am Heart J. 2007 Jan;153(1):98-104.


Left ventricular assist device as destination for patients undergoing intravenous inotropic therapy: a subset analysis from REMATCH (Randomized Evaluation of Mechanical Assistance in Treatment of Chronic Heart Failure).

Stevenson LW, Miller LW, Desvigne-Nickens P, Ascheim DD, Parides MK, Renlund DG, Oren RM, Krueger SK, Costanzo MR, Wann LS, Levitan RG, Mancini D; REMATCH Investigators.

Circulation. 2004 Aug 24;110(8):975-81. Epub 2004 Aug 16.


Intermittent inotropic infusions combined with prophylactic oral amiodarone for patients with decompensated end-stage heart failure.

Drakos SG, Kanakakis JV, Nanas S, Bonios M, Kaldara E, Katsaros F, Pantsios C, Nanas JN.

J Cardiovasc Pharmacol. 2009 Feb;53(2):157-61. doi: 10.1097/FJC.0b013e31819846cd.


In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE).

Abraham WT, Adams KF, Fonarow GC, Costanzo MR, Berkowitz RL, LeJemtel TH, Cheng ML, Wynne J; ADHERE Scientific Advisory Committee and Investigators; ADHERE Study Group.

J Am Coll Cardiol. 2005 Jul 5;46(1):57-64.


Sodium nitroprusside for advanced low-output heart failure.

Mullens W, Abrahams Z, Francis GS, Skouri HN, Starling RC, Young JB, Taylor DO, Tang WH.

J Am Coll Cardiol. 2008 Jul 15;52(3):200-7. doi: 10.1016/j.jacc.2008.02.083.


Renal function, digoxin therapy, and heart failure outcomes: evidence from the digoxin intervention group trial.

Shlipak MG, Smith GL, Rathore SS, Massie BM, Krumholz HM.

J Am Soc Nephrol. 2004 Aug;15(8):2195-203.


Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.

Anand IS, Bishu K, Rector TS, Ishani A, Kuskowski MA, Cohn JN.

Circulation. 2009 Oct 20;120(16):1577-84. doi: 10.1161/CIRCULATIONAHA.109.853648. Epub 2009 Oct 5.


Six minute walk test predicts long-term all-cause mortality and heart failure rehospitalization in African-American patients hospitalized with acute decompensated heart failure.

Alahdab MT, Mansour IN, Napan S, Stamos TD.

J Card Fail. 2009 Mar;15(2):130-5. doi: 10.1016/j.cardfail.2008.10.006. Epub 2008 Dec 5.


Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure.

Cohen-Solal A, Logeart D, Huang B, Cai D, Nieminen MS, Mebazaa A.

J Am Coll Cardiol. 2009 Jun 23;53(25):2343-8. doi: 10.1016/j.jacc.2009.02.058.


Morphine and outcomes in acute decompensated heart failure: an ADHERE analysis.

Peacock WF, Hollander JE, Diercks DB, Lopatin M, Fonarow G, Emerman CL.

Emerg Med J. 2008 Apr;25(4):205-9. doi: 10.1136/emj.2007.050419.


Influence of blood pressure on the effectiveness of a fixed-dose combination of isosorbide dinitrate and hydralazine in the African-American Heart Failure Trial.

Anand IS, Tam SW, Rector TS, Taylor AL, Sabolinski ML, Archambault WT, Adams KF, Olukotun AY, Worcel M, Cohn JN.

J Am Coll Cardiol. 2007 Jan 2;49(1):32-9. Epub 2006 Dec 14.


Low-dose oral enoximone enhances the ability to wean patients with ultra-advanced heart failure from intravenous inotropic support: results of the oral enoximone in intravenous inotrope-dependent subjects trial.

Feldman AM, Oren RM, Abraham WT, Boehmer JP, Carson PE, Eichhorn E, Gilbert EM, Kao A, Leier CV, Lowes BD, Mathier MA, McGrew FA, Metra M, Zisman LS, Shakar SF, Krueger SK, Robertson AD, White BG, Gerber MJ, Wold GE, Bristow MR; EMOTE Study Group.

Am Heart J. 2007 Nov;154(5):861-9. Epub 2007 Sep 6.


Effects of continuous aortic flow augmentation in patients with exacerbation of heart failure inadequately responsive to medical therapy: results of the Multicenter Trial of the Orqis Medical Cancion System for the Enhanced Treatment of Heart Failure Unresponsive to Medical Therapy (MOMENTUM).

Greenberg B, Czerska B, Delgado RM, Bourge R, Zile MR, Silver M, Klapholz M, Haeusslein E, Mehra MR, Mather P, Abraham WT, Neaton JD, Brown BS, Parker IC, Konstam MA; MOMENTUM Investigators and Coordinators.

Circulation. 2008 Sep 16;118(12):1241-9. doi: 10.1161/CIRCULATIONAHA.108.773275. Epub 2008 Sep 2.


Hemodynamics, diuretics, and nesiritide: a retrospective VMAC analysis.

Young JB, Cheng M, Mills RM.

Clin Cardiol. 2009 Sep;32(9):530-6. doi: 10.1002/clc.20620.


Associations of gender and etiology with outcomes in heart failure with systolic dysfunction: a pooled analysis of 5 randomized control trials.

Frazier CG, Alexander KP, Newby LK, Anderson S, Iverson E, Packer M, Cohn J, Goldstein S, Douglas PS.

J Am Coll Cardiol. 2007 Apr 3;49(13):1450-8. Epub 2007 Mar 21.


Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis.

Adams KF Jr, Patterson JH, Gattis WA, O'Connor CM, Lee CR, Schwartz TA, Gheorghiade M.

J Am Coll Cardiol. 2005 Aug 2;46(3):497-504.


Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE Trial.

Gheorghiade M, Rossi JS, Cotts W, Shin DD, Hellkamp AS, PiƱa IL, Fonarow GC, DeMarco T, Pauly DF, Rogers J, DiSalvo TG, Butler J, Hare JM, Francis GS, Stough WG, O'Connor CM.

Arch Intern Med. 2007 Oct 8;167(18):1998-2005.


Effect of baseline and changes in systolic blood pressure over time on the effectiveness of valsartan in the Valsartan Heart Failure Trial.

Anand IS, Rector TS, Kuskowski M, Thomas S, Holwerda NJ, Cohn JN.

Circ Heart Fail. 2008 May;1(1):34-42. doi: 10.1161/CIRCHEARTFAILURE.107.736975.


Effectiveness of hydralazine/isosorbide dinitrate in racial/ethnic subgroups with heart failure.

Hammermeister KE, Fairclough D, Emsermann CB, Hamman R, Ho M, Phibbs S, Plomondon M, Valuck R, West D, Steiner JF.

Clin Ther. 2009 Mar;31(3):632-43. doi: 10.1016/j.clinthera.2009.03.019.


Supplemental Content

Support Center